TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing

TG THERAPEUTICS, INC.

Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.
Safety and tolerability of consolidated first infusion were consistent with established BRIUMVI profile; no Grade 3 or higher infusion reactions occurred.
Supplemental BLA submission targeted for second half of 2026 based on these results.
If approved, BRIUMVI would be the first and only IV anti-CD20 therapy initiated with a single infusion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.